Please assess the completion status of the following clinical trial:

Trial Title: MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 20 years~2. ≥ 6 weeks since the last stroke~3. ≥ 2 points in the focal spasticity of wrist flexor and ≥ 1 points at least one of elbow flexor and finger flexor as measured on MAS(0 to 4)~4. Targeted one functional disability item (i.e., hygiene, dressing, pain, or cosmesis) with a rating of 2 or greater on DAS (0 to 3)~5. Informed consent has been obtained.~Exclusion Criteria:~1. Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis~2. History(within 6 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb~3. History(within 6 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb~4. Fixed joint/muscle contracture~5. Severe atrophy~6. Concurrent treatment with an intrathecal baclofen~7. History(within 3 months of screening visit) Planned(during study period) treatment with Botulinum Toxin~8. Known allergy or sensitivity to study medication or its components~9. Concurrent or planed Muscle relaxants and/or benzodiazepine medication~   * If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed.~10. Current Physical, occupational, Splinting therapy~    * If these therapy regimens will be permitted if they has been stable in the one month before screening;no treatment and no changes are planned during the study.~11. Patient who are participating in other clinical trials at the screening~12. Females who are pregnant, breatfeeding,or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of centraception.~13. Patients who are not eligible for this study at the discretion of the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Meditoxin® (Type: EXPERIMENTAL): Botulinum toxin type A
- Botox® (Type: ACTIVE_COMPARATOR): Botulinum Toxin type A

Based on this trial design, predict the completion outcome and termination type (if applicable).